Sugi Predict

Sugi Predict / Compounds / SCHEMBL149865

SCHEMBL149865

SCHEMBL149865

O=C(Cc1cccc(F)c1)c1ccccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ MAPT P10636 3/20 0.61
▸ LMNA P02545 3/20 0.61
▸ KDM4E B2RXH2 3/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ HPGD P15428 2/20 0.61
▸ ALOX12 P18054 2/20 0.61
▸ TSHR P16473 1/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ CNR2 P34972 1/20 0.48
▸ PIK3CA P42336 1/20 0.47
▸ ALOX5 P09917 1/20 0.46
▸ MAOA P21397 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ MPO P05164 1/20 0.44
▸ CYP19A1 P11511 1/20 0.44
▸ MAPK1 P28482 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29895835 0.87 HTT (0.50) HTTMEN1KMT2AMAPTLMNA
SCHEMBL150248 0.87 HTT (0.50) HTTMEN1KMT2AMAPTLMNA
SCHEMBL11566 0.87 MAPT (0.53) HTTMEN1KMT2AMAPTLMNA
SCHEMBL10560970 0.84 LMNA (0.54) HTTMEN1KMT2AMAPTLMNA
SCHEMBL20901402 0.83 ALOX5 (0.55) HTTMEN1KMT2AMAPTLMNA
SCHEMBL8956234 0.83 SRC (0.47) HTTMEN1KMT2AMAPTLMNA
SCHEMBL10561782 0.83 PIK3CA (0.68) HTTMEN1KMT2AMAPTLMNA
SCHEMBL11100 0.82 HPGD (0.47) HTTMEN1KMT2AMAPTLMNA
SCHEMBL30494456 0.82 HPGD (0.47) HTTMEN1KMT2AMAPTLMNA
SCHEMBL8376 0.81 HPGD (0.56) HTTMEN1KMT2AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
WO-2023130334-A1 METHOD FOR PREPARING CHROMEN-4-ONE COMPOUND AND INTERMEDIATE THEREOF 同润生物医药(上海)有限公司 2023-07-13 — — WO disclosed
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals RHIZEN PHARMACEUTICALS AG (CH) 2022-10-25 — — US disclosed
US-11466006-B2 Dual selective PI3 delta and gamma kinase inhibitors RHIZEN PHARMACEUTICALS AG (CH) 2022-10-11 — — US disclosed
US-20210403475-A1 NOVEL SELECTIVE PI3K DELTA INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 — — US disclosed
US-10981919-B2 Selective PI3K delta inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2021-04-20 — — US disclosed
US-20210032248-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2021-02-04 — — US disclosed
US-10851107-B2 Dual selective P13 delta and gamma kinase inhibitors RHIZEN PHARMACEUTICALS SA (CH) 2020-12-01 — — US disclosed
EP-2844647-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS Rhizen Pharmaceuticals S.A. (CH) 2015-03-11 — — EP disclosed
WO-2014195888-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS SA (CH) 2014-12-11 — — WO disclosed
US-20140364447-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2014-12-11 — — US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20140011819-A1 NOVEL SELECTIVE PI3K DELTA INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2014-01-09 — — US disclosed
WO-2014006572-A1 SELECTIVE PI3K DELTA INHIBITORS RHIZEN PHARMACEUTICALS SA (CH) 2014-01-09 — — WO disclosed
WO-2013164801-A1 PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2- (1 -HYDROXY- ALKYL) - CHROMEN - 4 - ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS RHIZEN PHARMACEUTICALS SA (CH) 2013-11-07 — — WO disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885MEN1 4673/4885KMT2A 3137/4885
US-20210032248-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS PRKCZ, PIK3CD, PRKCE HTT 3921/4885MEN1 4217/4885KMT2A 3991/4885
US-20140011819-A1 NOVEL SELECTIVE PI3K DELTA INHIBITORS PIK3CD, PIK3R5, PIK3C2B HTT 3496/4885MEN1 4030/4885KMT2A 3719/4885
US-11478481-B2 Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals CYP4B1, ADH1A, CYP1A2 HTT 2015/4885MEN1 778/4885KMT2A 3271/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885MEN1 4673/4885KMT2A 3137/4885
US-10851107-B2 Dual selective P13 delta and gamma kinase inhibitors PRKCZ, PRKCH, PRKCG HTT 3719/4885MEN1 3613/4885KMT2A 4308/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885MEN1 4673/4885KMT2A 3137/4885
US-11466006-B2 Dual selective PI3 delta and gamma kinase inhibitors PRKCZ, PIK3CD, PRKCE HTT 3921/4885MEN1 4217/4885KMT2A 3991/4885
US-10981919-B2 Selective PI3K delta inhibitors PIK3CD, PIK3C2B, PIK3R5 HTT 3615/4885MEN1 4017/4885KMT2A 3742/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A HTT 3291/4885MEN1 3578/4885KMT2A 3863/4885
US-20140364447-A1 DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS PRKCZ, PIK3CD, PRKCE HTT 3921/4885MEN1 4217/4885KMT2A 3991/4885
US-20210403475-A1 NOVEL SELECTIVE PI3K DELTA INHIBITORS PIK3CD, PIK3R5, PIK3C2B HTT 3496/4885MEN1 4030/4885KMT2A 3719/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885MEN1 4673/4885KMT2A 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.